Thuja Capital
VC Fund
Utrecht, The Netherlands
Thuja Capital is a VC fund in Utrecht focused on Biotechnology and Health Care. Thuja Capital invests in early stage medical product innovations for diagnosis, cure, care or prevention.
- Total investments:
- 62
- Last investment:
- Lead investor:
- 55%
- Fund size:
- $36M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Thuja Capital invests in
Stages Thuja Capital invests in
Countries Thuja Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Investment Focus
Industry
- Biotechnology 30 (48%)
- Health Care 20 (32%)
- Medical 19 (31%)
- Therapeutics 8 (13%)
- Medical Device 7 (11%)
Stage
- Funding Round 19 (31%)
- Series A 16 (26%)
- Seed 10 (16%)
- Series B 6 (10%)
- Post-IPO Equity 3 (5%)
Country
- The Netherlands 22 (35%)
- Belgium 6 (10%)
- Germany 5 (8%)
- United States 5 (8%)
- France 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michel Briejer
Managing Partner
|
Managing Partner | Total investments: 10 | Find email | |
Evan Castiglia
Partner
|
Partner | Total investments: 3 | Find email | |
Florian Ludwig
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
|
Harrold van Barlingen
Founder and Managing Partner
|
Founder and Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tacalyx
|
Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $12.9M / Seed / Apr 29, 2026 | |
ATRO Medical
|
ATRO Medical is a spin-out from DSM and Radboudumc and builds on the knowledge developed in the Public-Private Collaboration BioMedical Materials that started in 2010 with a consortium of universities, private companies, and financial support from the Dutch government. The collaboration between the clinical, biomechanical, and polymer expertise hascreated the base for the Trammpolin design and the development towards a prototype. | $3.5M / Venture - Series Unknown / Feb 24, 2026 | |
Pan Cancer T
|
Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors. | $5.8M / Seed / Dec 08, 2025 | |
Salvia BioElectronics
|
Salvia BioElectronics develops innovative neuromodulation devices aimed at treating migraines. The company focuses on creating a paper-thin implant that delivers gentle electrical pulses to specific nerves, helping to alleviate migraine symptoms. Salvia BioElectronics is dedicated to advancing its technology through ongoing research and developmentefforts. With recent funding, the company works to bring its migraine therapy to market, offering a new approach to pain management for patients. The emphasis is on improving patient outcomes through effective neuromodulation therapy. | $60.1M / Series B / May 27, 2025 | |
Alesta Therapeutics
|
Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic approaches to treat cancer | $67M / Series A / Jan 08, 2025 | |
Alveron Pharma
|
Alveron Pharma develops treatment for hemorrhagic stroke, a severe unmet medical need. Alveron’s drug OKL-1111 strongly reduces hematoma expansion in a mouse model of intracranial hemorrhage. As an injection solution that is ready to use, OKL-1111 is being developed to do away with a laborious pre-treatment process. | $5.3M / Seed / Dec 06, 2024 | |
|
Pan Cancer T
|
Pan-Cancer T is a biotechnology spin-out from Erasmus MC, Rotterdam, the Netherlands dedicated to discovering and developing T cell receptor (TCR) T cell therapies. The company exploits 20 years of pioneering research in the field of adoptive T-cell therapies. This foundation serves as a springboard towards breakthrough therapies for solid tumors. | $4.6M / Seed / Jul 11, 2024 | |
|
Tacalyx
|
Tacalyx develops therapeutics targeting cancer-specific carbohydrate antigens on the surface of metastatic malignant tumors where no satisfactory treatments exist.The name Tacalyx is derived from TACA (Tumor Associated Carbohydrate Antigen) and ‘lyx’ from the term Glycocalyx, the glycan-containing layer covering cells. Cancer cells differ fromnormal cells by displaying aberrant carbohydrate structures on their surfaces promoting metastasis, angiogenesis or suppression of the immune system. TACAs result from the aberrant glycosylation that is seen with transformation to a tumor cell and represent attractive targets for cancer treatment since they are displayed with high cancer specificity and enhance tumor virulence via the mentioned diverse mechanisms. | $7.5M / Seed / Jun 11, 2024 | |
Artica Therapeutics
|
Artica Therapeutics specializes in biotechnological research and development for medical devices, pharmaceutical processes, and food. | $12.7M / Seed / Nov 02, 2023 | |
Synerkine Pharma
|
Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. The company's protein targets common regulatory mechanisms in different types of chronic pain and has unique properties, enabling patients to effectively reduce pain in multiple pre-clinical models. | $5.6M / Series A / Oct 12, 2023 | |
| See all 62 investments → | |||
Co-Investors
BOM
8 deals together
BioGeneration Ventures
5 deals together
DSM Venturing
5 deals together
OostNL
5 deals together
InnovationQuarter
4 deals together
Van Herk Ventures
4 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Thuja Capital invest in?
Thuja Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 62 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Thuja Capital?
Public channels for Thuja Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Thuja Capital?
The team at Thuja Capital includes Michel Briejer (Managing Partner), Evan Castiglia (Partner) and Florian Ludwig (Venture Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
